Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Thermo Fisher, Wells Fargo, Nutrien And More On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, picked Horizon Kinetics Inflation Beneficiaries ETF (NYSE:INFL).

Benzinga • Sep 10, 2026

Here are the stocks to favor in the fourth quarter — and those you should avoid

Large caps tend to outperform small caps as year's end approaches.

Market Watch • Sep 10, 2026

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.

Zacks Investment Research • Sep 8, 2026

Should You Continue to Hold TMO Stock in Your Portfolio?

Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.

Zacks Investment Research • Sep 4, 2026

Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader to Help Simplify Protein, Cell and Microbial Analysis

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the launch of the Thermo Scientific™ Multiskan™ Ease Absorbance Microplate Reader, designed to support protein quantification, enzyme-linked immunosorbent assays (ELISAs), cell viability studies, microbial growth monitoring and other routine laboratory applications with simplified operation and dependable performance. Laboratories performing absorbance-based analysis are under increasing pressure to generate reliable data.

Business Wire • Sep 2, 2026

Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

ETF Trends • Sep 2, 2026

TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.

Zacks Investment Research • Sep 1, 2026

Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 9:15 a.m. (ET).You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com.About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leade.

Business Wire • Sep 1, 2026

Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Research

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ EMPAD™ G2 detector, a new detector designed to help researchers see and understand materials in unprecedented detail. EMPAD G2 enables high-speed four-dimensional scanning transmission electron microscopy (4D STEM), an advanced form of electron microscopy that captures far more information about a material than a standard image, helping researchers better.

Business Wire • Aug 27, 2026